Unresectable Hepatocellular Carcinoma (uHCC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Unresectable Hepatocellular Carcinoma (uHCC) Market Outlook
Thelansis’s “Unresectable
Hepatocellular Carcinoma (uHCC) Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2024 To 2034" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Unresectable
Hepatocellular Carcinoma (uHCC) treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Unresectable Hepatocellular Carcinoma
(uHCC) Overview
Unresectable
hepatocellular carcinoma (uHCC) is defined as a liver tumor that is ineligible
for resection therapy due to the extent of disease. This includes patients who
are unsuitable for surgery due to the tumor’s location in the liver, patients
older than 75 years, or those who refuse surgical interventions. This cohort
encompasses a diverse range of patients with variations in tumor size, number,
location, and underlying liver function. Historically, sorafenib was the sole
approved first-line therapeutic agent for uHCC. Subsequently, regorafenib and
other agents received approval as second-line treatments for uHCC when
sorafenib was either intolerable or ineffective. Recent advancements have
introduced immuno-oncology (IO) immune checkpoint inhibitor combinations as
preferred first-line treatments. Notably, the combination of atezolizumab with
bevacizumab (AB) has emerged as a preferred first-line treatment option for
patients with uHCC.
Geography coverage:
G8 (United States, EU5 [France,
Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust
research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal
articles, third-party research databases)
Deliverables format and
updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated
dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant
support
*As per Thelansis’s policy, we
ensure that we include all the recent updates before releasing the report
content and market model.
Salient features of Market
Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market forecasts validated
through the top-down sales methodology
- Covers clinically and commercially-relevant patient
populations/ line of therapies
- Annualized drug-level sales and patient share
projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management
strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of
incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and
patient share?
- Which events will have the greatest impact on the
market’s trajectory?
- What insights do interviewed experts provide on
current and emerging treatments?
- Which pipeline products show the most promise, and
what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations
for target profiles?
- What key regulatory and payer requirements must be
met to secure drug approval and favorable market access?
- and more…
Comments
Post a Comment